Antiangiogenic tumor therapy

被引：10

作者：

Davis, DW ^{[1
]}

McConkey, DJ ^{[1
]}

Zhang, W ^{[1
]}

Herbst, RS ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

来源：

BIOTECHNIQUES | 2003年 / 34卷 / 05期

关键词：

D O I：

10.2144/03345dd01

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：1048 / +

页数：9

共 99 条

[51] VASCULAR-PERMEABILITY FACTOR, AN ENDOTHELIAL-CELL MITOGEN RELATED TO PDGF [J].

KECK, PJ ;

HAUSER, SD ;

KRIVI, G ;

SANZO, K ;

WARREN, T ;

FEDER, J ;

CONNOLLY, DT .

SCIENCE, 1989, 246 (4935) :1309-1312

[52] Clinical translation of angiogenesis inhibitors [J].

Kerbel, R ;

Folkman, J .

NATURE REVIEWS CANCER, 2002, 2 (10) :727-739

[53] A cancer therapy resistant to resistance [J].

Kerbel, RS .

NATURE, 1997, 390 (6658) :335-336

[54] Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches [J].

Kerbel, RS ;

Yu, J ;

Tran, J ;

Man, S ;

Viloria-Petit, A ;

Klement, G ;

Coomber, BL ;

Rak, J .

CANCER AND METASTASIS REVIEWS, 2001, 20 (1-2) :79-86

[55]

Ko YJ, 2001, CLIN CANCER RES, V7, P800

[56]

Kobayashi T, 2003, CANCER RES, V63, P60

[57]

Kohn EC, 2001, CLIN CANCER RES, V7, P1600

[58] Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors [J].

Kuenen, BC ;

Rosen, L ;

Smit, EF ;

Parson, MRN ;

Levi, M ;

Ruijter, R ;

Huisman, H ;

Kedde, MA ;

Noordhuis, P ;

van der Vijgh, WJF ;

Peters, GJ ;

Cropp, GF ;

Scigalla, P ;

Hoekman, K ;

Pinedo, HM ;

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1657-1667

[59] Proteomics: a technology-driven and technology-limited discovery science [J].

Lee, KH .

TRENDS IN BIOTECHNOLOGY, 2001, 19 (06) :217-222

[60]

Levitt NC, 2001, CLIN CANCER RES, V7, P1912

← 1 2 3 4 5 6 7 8 9 10 →